Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy

NCT03394365 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.

NCT NCT03394365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03394365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy
Lead sponsor
Pierre Fabre Medicament
Phase
Phase 3
Overall status
Recruiting
Start date
December 29, 2017
Completion date
August 31, 2030
Enrollment
115 (estimated)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

allogeneic hematopoietic cell transplant, epstein-barr virus+ associated post-transplant lymphoproliferative disease (ebv+ ptld), lymphoproliferative disorders, solid organ transplant complications, stem cell transplant complications